Holen Sie sich die Stockscreener-App
44.34
0.89%
-0.40
Vorhandelsmarkt:
46.06
1.72
+3.88%
Schlusskurs vom Vortag:
$44.74
Offen:
$44.82
24-Stunden-Volumen:
974.68K
Relative Volume:
0.85
Marktkapitalisierung:
$3.51B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-7.4646
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
-7.35%
1M Leistung:
-11.04%
6M Leistung:
-1.88%
1J Leistung:
+30.07%
1-Tages-Spanne:
$44.15
$45.37
1-Wochen-Bereich:
$44.15
$48.23
52-Wochen-Spanne:
$29.02
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
44.34 | 3.55B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
How did PTCT's revenue and expenses trends shift in Q4 2024 compared to previous quarters - AInvest
PTC Therapeutics' Sephience Approval: A $1B+ Rare Disease Opportunity Unfolding - AInvest
FDA Approval Sparks Bullish Momentum In PTC Therapeutics — Here’s What Happened - Stocktwits
US FDA approves PTC Therapeutics' metabolic disorder drug - Reuters
PTC Therapeutics (PTCT) Gains FDA Approval for Sephience in Phenylketonuria - GuruFocus
PTC Therapeutics Gains FDA Approval for Sephience - TipRanks
PTC Therapeutics stock soars after FDA approval of PKU treatment By Investing.com - Investing.com Canada
PTC Therapeutics gets FDA nod for phenylketonuria treatment - Seeking Alpha
FDA Approval Boosts PTC Therapeutics (PTCT) with Sephience Launch - GuruFocus
PTC Therapeutics: Pioneering Rare Disease Innovation with Sephience and Kebilidi - AInvest
PTC Therapeutics' Sephience™: A Game-Changer for PKU and Shareholder Value - AInvest
FDA approves PTC Therapeutics’ Sephience for phenylketonuria treatment By Investing.com - Investing.com India
PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) | PTCT Stock News - GuruFocus
Is it the right time to buy PTC Therapeutics Inc. stockValue Investing Recommendation For Every Investor - jammulinksnews.com
Breakthrough PKU Treatment: FDA Approves PTC's Sephience for All Ages and Disease Subtypes - Stock Titan
Oversold Conditions For PTC Therapeutics - Nasdaq
Cerity Partners LLC Buys New Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
What makes PTC Therapeutics Inc. stock price move sharplyExplosive earnings growth - jammulinksnews.com
How does PTC Therapeutics Inc. compare to its industry peersBreakout Stocks Recommendation With Proven Results - jammulinksnews.com
Leerink Partnrs Cuts Earnings Estimates for PTC Therapeutics - MarketBeat
What institutional investors are buying PTC Therapeutics Inc. stockCapitalize on momentum-driven opportunities - jammulinksnews.com
Why is PTC Therapeutics Inc. stock attracting strong analyst attentionGet daily updates on market movers and shakers - jammulinksnews.com
Does PTC Therapeutics Inc. stock perform well during market downturnsBuild a diversified portfolio for sustainable growth - jammulinksnews.com
What are the latest earnings results for PTC Therapeutics Inc.Breakthrough investment results - jammulinksnews.com
How Resilient Is PTC Therapeutics Inc. Stock During Economic DownturnsLong Term Secure Gain Stocks - metal.it
What is the risk reward ratio of investing in PTC Therapeutics Inc. stockDiscover stocks with massive upside potential - jammulinksnews.com
When is PTC Therapeutics Inc. stock expected to show significant growthRapid return acceleration - jammulinksnews.com
Universal Beteiligungs und Servicegesellschaft mbH Buys 36,365 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Neo Ivy Capital Management Makes New Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results - Quantisnow
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - Quantisnow
Leerink Partners Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $50 - 富途牛牛
PTC Therapeutics Inc. Stock Analysis and ForecastUnrivaled growth potential - PrintWeekIndia
Cwm LLC Buys 14,139 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Pinnacle Associates Ltd. Cuts Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Cautious Outlook on PTC Therapeutics: Sepiapterin’s Limited Potential to Offset Declining DMD Revenues - TipRanks
PTC Therapeutics Surges to 488th in Daily Rankings with 2.35 Billion Trading Volume Despite Slight Price Decline - AInvest
8,196 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by Edgestream Partners L.P. - MarketBeat
Huntington's Disease Clinical, Companies, Therapeutic - openPR.com
What analysts say about PTC Therapeutics Inc. stockPhenomenal wealth increase - jammulinksnews.com
Is PTC Therapeutics Inc. a good long term investmentExceptional market positioning - jammulinksnews.com
What drives PTC Therapeutics Inc. stock priceRobust investment performance - jammulinksnews.com
Leigh Syndrome Market Research Report 2025-2035 | Competitive Analysis of PTC Therapeutics, Pharming Group, Edison Pharmaceuticals, Taysha Gene Therapies, and Thiogenesis Therapeutics - Yahoo Finance
Pega to Announce Financial Results for the Second Quarter of 2025 and Host Conference Call and Webcast - Yahoo.co
Pierre Gravier Sells 2,516 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.32%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):